What is Twist Bioscience Corporation (TWST)?

Twist Bioscience Corporation (TWST) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of TWST?

The current price of TWST is $152.78. Prices are updated in real time on Stocks360.

What is TWST's price-to-earnings (PE) ratio?

TWST's trailing twelve-month PE ratio is -68.82, based on current price and earnings per share data available on Stocks360.

What is TWST's market capitalization?

TWST's market capitalization is $10,057,874,072.00, placing it in the large-cap tier.

Twist Bioscience Corporation (TWST)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$152.78

Market Cap

$10.06B

PE (TTM)

-68.82

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

2.19

Day Range

$148.00 – $167.27

52-wk Range

$23.30 – $219.71

Avg Volume

N/A

Volume

3.40M

Twist Bioscience Corporation (TWST) is a publicly traded company in the Healthcare sector. Latest price: $152.78. Market cap $10.06B. Trailing PE -68.82. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $32.89 2026-10-30 · $152.78 (+364.52%)

Earnings

Most Recent

Aug 3, 2026

EPS $-0.56 vs est. $-0.51

Missed by $0.05

Next Earnings

Nov 12, 2026

EPS estimate $-0.38

Proprietary Signals

Signal snapshot temporarily unavailable.

About Twist Bioscience Corporation

Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, Californi…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-68.82×
P/S (TTM)	23.29×
P/B	21.39×
PEG	1.05×
P/FCF (TTM)	-108.01×
EV / EBITDA	-93.09×
EV / Sales	23.24×
Earnings Yield	-1.43%
Free Cash Flow Yield	-0.93%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$10.03B
Revenue (TTM)	$431.80M
Net Income (TTM)	-$144.23M
Free Cash Flow (TTM)	-$93.12M
Net Debt	-$23.85M
Working Capital	$201.04M
Gross Margin	51.97%
Operating Margin	-31.91%
Net Margin	-31.66%
Return on Equity	-29.89%
Return on Invested Capital	-24.57%